Prelude Therapeutics Inc logo

PRLD

Prelude Therapeutics Inc

$8.23

Earnings Summary

Revenue
$0Mn
Net Profits
$-29.47Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Prelude Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Prelude Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Prelude Therapeutics Inc’s net profit fell -38.33% since last year same period to $-29.47Mn in the Q1 2022. On a quarterly growth basis, Prelude Therapeutics Inc has generated 10.28% jump in its net profits since last 3-months.

Net Profit Margins:

Prelude Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Prelude Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Prelude Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.63
EPS Estimate Current Year
-0.63

Highlights

EPS Estimate Current Quarter:

Prelude Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.63 - a 3.08% jump from last quarter’s estimates.

EPS Estimate Current Year:

Prelude Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.63.

Key Ratios

Key ratios of the Prelude Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.63
Return on Assets (ROA)
-0.25
Return on Equity (ROE)
-0.42
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Prelude Therapeutics Inc’s earning per share (EPS) fell -34.04% since last year same period to -0.63 in the Q1 2022. This indicates that the Prelude Therapeutics Inc has generated -34.04% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Prelude Therapeutics Inc’s return on assets (ROA) stands at -0.25.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Prelude Therapeutics Inc’s return on equity (ROE) stands at -0.42.

Dividend Per Share (DPS):

Prelude Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.65
-0.63
3.08%

Company Information

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

Organisation
Prelude Therapeutics Inc
Employees
68
Industry
Health Technology